News | Rewind Therapeutics

Rewind Therapeutics expands Scientific Advisory Board with addition of Professors Robin Franklin and Catherine Lubetzki, bringing further expertise in myelin and multiple sclerosis research

February 6, 2019

Rewind Therapeutics Builds Scientific Advisory Board to Accelerate Its Development of New Therapies for Myelin-Related Diseases

October 10, 2018

Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer

October 3, 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

January 4, 2018

Rewind Therapeutics Secures 15.2 M EURO to Develop Novel Remyelination Therapies

January 4, 2018